Abstract: A floor covering includes a plastics core, which has an upper side and a lower side, a functional layer and a reinforcement mat arranged on the upper side, and which has fibers and voids located therebetween, wherein the reinforcement mat is located between the upper side of the plastics core and the functional layer, the reinforcement mat and the functional layer constituting a preproduced unit, in which the reinforcement mat is fastened to the functional layer, wherein the plastics core is joined with the preproduced unit in such a way that the plastics core is joined with the fibers of the reinforcement mat and through the voids of the reinforcement mat with the functional layer such that the floor covering has a high degree of dimensional stability, and a method for producing the floor covering.

Abstract: The invention relates to a method for evaluation of a compound-target interaction in vivo, comprising the steps of administering the compound to an animal, taking a body fluid sample of the animal, determining the concentration of the compound in the body fluid sample, taking a cellular sample of the animal containing the target, preparing a protein preparation of said cellular sample, providing an immobilised ligand capable of binding to the target, contacting the protein preparation with the immobilised ligand under conditions allowing the formation of a complex between the immobilised ligand and the target, determining the amount of complexes formed in step, and correlating the amount of complexes with the concentration of the compound in the body fluid sample.

Abstract: The present invention relates to methods for the identification and characterization (e.g. selectivity profiling) of HDAC interacting compounds using protein preparations derived from cells endogenously expressing HDACs or cell preparations containing said HDACs.

Abstract: The invention provides in a first aspect a method for the identification of an ZAP-70 interacting compound, comprising the steps of a) providing a protein preparation containing phosphorylated ZAP-70, b) contacting the protein preparation with aminopyrido-pyrimidine ligand 24 immobilized on a solid support under conditions allowing the formation of an aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex, c) incubating the aminopyrido-pyrimidine ligand 24—phosphorylated ZAP-70 complex with a given compound, and d) determining whether the compound is able to separate phosphorylated ZAP-70 from the immobilized aminopyrido-pyrimidine ligand 24.

Abstract: The invention relates to compounds of formula (I) wherein R1 to R9 and R4a have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, R3, R8, R9 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

Abstract: The present invention relates to methods for the characterization of enzymes or of enzyme-compound complexes, wherein the enzyme is obtained from a protein preparation with the help of at least one broad spectrum ligand immobilized on a solid support and wherein the enzyme is characterized by mass spectrometry. These methods are useful for the screening of non-immobilized compound libraries, selectivity profiling of lead compounds and mechanism of action studies in living cells.

Abstract: The present invention relates to a process for the isolation and identification of pharmaceutically relevant target compounds (TC) from a sample, said sample being derived from a living organism, wherein said target compound(s) bind(s) to a compound of interest (COI) under physiological conditions, said compound of interest (COI) being associated with a given impaired condition or disease. Furthermore, the present invention relates to a process for the identification of a pharmaceutically effective compound useful for preventing and/or treating a given impaired condition or disease, wherein said compound is identified by its binding to a relevant target compound (TC) that has been identified and isolated according to the above mentioned process.